NasdaqGS:ALNYBiotechs
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY?
In early June 2026, Inceptive Nucleics announced a collaboration with Alnylam Pharmaceuticals worth up to US$2.00 billion, including US$30 million in upfront cash and equity, to integrate generative AI models into Alnylam’s RNAi drug discovery engine while Alnylam also broadened its European commercial reach via GENESIS Pharma.
A distinctive aspect of this alliance is Alnylam’s access to Inceptive’s frontier AI talent, including the co-inventor of the Transformer architecture, aimed at using...